Nuvectis Pharma (NVCT) Corporate presentation summary

Strategic partnerships and financial position

• Entered a transformative licensing agreement with Haisco Pharmaceutical Group, leveraging their experience and portfolio to advance clinical programs.

• Completed a $115M follow-on offering in July 2026, with cash reserves of approximately $120M, providing runway into the first half of 2029.

• Positioned to reach key inflection points with multiple near-term clinical and regulatory catalysts expected.

Pipeline overview and clinical progress

• Focused on precision medicine for complement-mediated diseases and cancer, with three main assets: Ciprocopan (NXP100), NXP200, and NXP900.

• Ciprocopan (NXP100) is an oral, once-daily Factor B inhibitor with first global approval in China for treatment-naïve PNH and a pending application for previously treated PNH.

• NXP200 is a brain-penetrant, paradox-breaker BRAF inhibitor in Phase 1b expansion for solid tumors and primary brain cancer in China.

• NXP900 is a SRC/YES1 kinase inhibitor, enrolling Phase 1b combination studies in NSCLC and planning a combination study in pancreatic cancer.

Ciprocopan (NXP100) clinical data and market potential

• Demonstrated superiority over Soliris in treatment-naïve PNH, with 59.5% of patients achieving hemoglobin >12 g/dL versus 8.3% for Soliris.

• Achieved a 52.8% response rate in previously treated PNH patients, meeting all primary and secondary endpoints.

• Showed robust proteinuria reduction and eGFR improvement in Phase 2 IgAN, supporting disease-modifying potential.

• Positioned as a potential best-in-class therapy, differentiated by once-daily oral dosing and broad development program.